STOCKHOLM-FASHION
14.8.2024 14:34:33 CEST | Business Wire | Press release
Stockholm Fashion District is revolutionizing the fashion industry by offering a vibrant platform for designers, creatives and buyers to connect. Unlike traditional trade platforms that occur just twice a year, Stockholm Fashion District hosts multiple trade shows annually - pushing the boundaries of industry conventions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240813925340/en/
Catwalk on the Grand Opening of Fashion Week Trade, 12-16 August 2024 (Photo: Business Wire)
This innovative approach allows creatives in the industry to connect, inspire and gain valuable market exposure, all under the same roof.
"The fashion industry is ever changing, therefore initiatives in trade conventions are crucial to reflect the current landscape and its eager pioneers" says Helena Walker, CEO Stockholm Fashion District
During this Fashion Week Trade, 12-16 August, Stockholm Fashion District opens its doors to one of the biggest trade events of the year. By incorporating 700 fashion brands, ranging from mid-market to premium, the event seamlessly blends different brands showcasing fashion, shoes and accessories.
With its purpose of bringing people together, the event will celebrate creativity and innovation by having fashion enthusiasts and professionals attending from all around the world. Relationships and businesses will grow.
"The world around us is definitely very challenging for our industry. Cooperation, flexibility, and transition are the way to the future, and we are a reliable player and meeting place for the industry. Together we create energy to find new opportunities." says Helena Walker, CEO Stockholm Fashion District
The fashion industry in Sweden is a significant contributor to the country's economy, generating a revenue of 173 billion SEK and employing around 40,000 people. Sweden is known for its emphasis on innovation, entrepreneurship, sustainability, and creativity - values that are reflected in the fashion industry.
Beyond the conventional twice-a-year fashion trade convention, Stockholm Fashion District is providing a year-round platform for designers, creatives and buyers to connect. Linking Swedish fashion enterprises to the global market, the area hosts 22 yearly sales-focused events in addition to its 143 showrooms that are open year-round. Along with collaborative opportunities and training sessions, Trade Partners Sweden supports with legal, logistical, and sales expertise. The organization supports fashion professionals all year round.
Fashion Week Trade is taking place between 12–16 August in Stockholm
Link to the program here
Link to the brand list here
For more information about the Swedish fashion industry, read the Fashion Transformation Report here.
ABOUT:
Stockholm Fashion District (SFD)
https://www.stockholmfash iondistrict.se
Trade Partners Sweden (TPS)
https://www.tradepartnerssweden.se/
Trade Partners Sweden is a member organization representing Swedish agents, suppliers, and distributors in fashion, shoes, and textiles. They are the founders of Stockholm Fashion District, a company that serves as the physical meeting place for the industry in Sweden and hosts events including Fashion Week Trade.
PRESS IMAGES:
Click here
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813925340/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom